TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy

Cancer Epidemiology

Volumn 34, Issue 4, 2010, Pages 490-493

  Henríquez Hernández, Luis Alberto ^a,b   Pérez, Leandro Fernández ^a,b   Hernández, Ana González ^b,c   de León, Antonio Cabrera ^b,c   Díaz Chico, Bonifacio ^a,b   Rosales, A Murias ^b,d  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b Madrid Spain   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

Adjuvant chemotherapy; Breast cancer; MTHFR; Multifocal tumour; PCR RFLP; Polymorphism; Risk factors

Indexed keywords

ARGININE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GENE PRODUCT; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROLINE; PROTEIN P53; PROTEIN TYMS; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MULTIDRUG RESISTANCE PROTEIN; THYMIDYLATE SYNTHASE; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; GENOTYPE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROGNOSIS; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53; P-GLYCOPROTEINS;

EID: 77955090112     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.03.004     Document Type: Article

References (35)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Bugano D.D., Conforti-Froes N., Yamaguchi N.H., Baracat E.C. Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol 2008, 29:313-320.
3. Tan S.H., Lee S.C., Goh B.C., Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008, 14:8027-8041.
4. Sharp L., Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 2004, 159:423-443.
5. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.B., Wilke H., et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997, 15:389-400.
6. Kawakami K., Omura K., Kanehira E., Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999, 19:3249-3252.
7. Zhai X., Gao J., Hu Z., Tang J., Qin J., Wang S., et al. Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. BMC Cancer 2006, 6:138.
8. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 2005, 23:533-537.
9. Powers H.J. Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr 2005, 135:2960S-2966S.
10. Goyette P., Sumner J.S., Milos R., Duncan A.M., Rosenblatt D.S., Matthews R.G., et al. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 1994, 7:551.
11. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
12. Macis D., Maisonneuve P., Johansson H., Bonanni B., Botteri E., Iodice S., et al. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 2007, 106:263-271.
13. Gibney M.J., Gibney E.R. Diet, genes and disease: implications for nutrition policy. Proc Nutr Soc 2004, 63:491-500.
14. Soussi T., Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1:233-240.
15. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365.
16. Xu Y., Yao L., Ouyang T., Li J., Wang T., Fan Z., et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005, 11:7328-7333.
17. Aoki M.N., da Silva do Amaral Herrera A.C., Amarante M.K., do Val Carneiro J.L., Fungaro M.H., Watanabe M.A. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009, 23:429-435.
18. Suspitsin E.N., Buslov K.G., Grigoriev M.Y., Ishutkina J.G., Ulibina J.M., Gorodinskaya V.M., et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 2003, 103:431-433.
19. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478.
20. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007, 67:9609-9612.
21. Zubor P., Lasabova Z., Hatok J., Stanclova A., Danko J. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep 2007, 18:211-217.
22. Turgut S., Yaren A., Kursunluoglu R., Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007, 38:539-544.
23. Cabrera de Leon A., Rodriguez Perez Mdel C., Almeida Gonzalez D., Dominguez Coello S., Aguirre Jaime A., Brito Diaz B., et al. Presentation of the " CDC de Canarias" cohort: objectives, design and preliminary results. Rev Esp Salud Publica 2008, 82:519-534.
24. Henriquez-Hernandez L.A., Murias-Rosales A., Hernandez Gonzalez A., Cabrera De Leon A., Diaz-Chico B.N., Mori De Santiago M., et al. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol Rep 2009, 22:1425-1433.
25. Marsh S., Collie-Duguid E.S., Li T., Liu X., McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999, 58:310-312.
26. Beckman G., Birgander R., Sjalander A., Saha N., Holmberg P.A., Kivela A., et al. Is p53 polymorphism maintained by natural selection?. Hum Hered 1994, 44:266-270.
27. Reljic A., Simundic A.M., Topic E., Nikolac N., Justinic D., Stefanovic M. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: the Croatian case-control study. Clin Biochem 2007, 40:981-985.
28. Pare L., Altes A., Ramon y Cajal T., Del Rio E., Alonso C., Sedano L., et al. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Anticancer Drugs 2007, 18:821-825.
29. Martin D.N., Boersma B.J., Howe T.M., Goodman J.E., Mechanic L.E., Chanock S.J., et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 2006, 6:257.
30. Kim D.H. The interactive effect of methyl-group diet and polymorphism of methylenetetrahydrofolate reductase on the risk of colorectal cancer. Mutat Res 2007, 622:14-18.
31. Razin A., Cedar H. DNA methylation and gene expression. Microbiol Rev 1991, 55:451-458.
32. Frigola J., Sole X., Paz M.F., Moreno V., Esteller M., Capella G., et al. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 2005, 14:319-326.
33. Lightfoot T.J., Barrett J.H., Bishop T., Northwood E.L., Smith G., Wilkie M.J., et al. Methylene tetrahydrofolate reductase genotype modifies the chemopreventive effect of folate in colorectal adenoma, but not colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:2421-2430.
34. Halsted C.H., Villanueva J.A., Devlin A.M., Chandler C.J. Metabolic interactions of alcohol and folate. J Nutr 2002, 132:2367S-2372S.
35. Giovannucci E., Rimm E.B., Ascherio A., Stampfer M.J., Colditz G.A., Willett W.C. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995, 87:265-273.